Izvorni znanstveni članak
https://doi.org/10.20471/acc.2024.63.s2.3
Systematic and Targeted Prostate Biopsy: a Five-Year Experience in a High-Volume Center
Toni Zekulić
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Tomislav Kuliš
orcid.org/0000-0002-0895-5691
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
*
Tvrtko Hudolin
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Luka Penezić
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Jerko Anđelić
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Tomislav Sambolić
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Bojan Čikić
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia
Nikola Knežević
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
Željko Kaštelan
; Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia
* Dopisni autor.
Sažetak
Prostate biopsy is the gold standard diagnostic tool for prostate cancer. The number
of targeted prostate biopsies based on multiparametric resonance imaging have increased in recent
years, and this method is becoming increasingly utilized in patients in repeat biopsy settings, but also
for biopsy-naive patients. The aim of this study was to analyze and present our results for the purpose
of self-control and education. In the time period between January 2018 and December 2022, there
were a total of 3385 prostate biopsies performed at the University Hospital Centre Zagreb. There were
2636 systematic (12 core) and 749 cognitive targeted biopsies, with an increasing trend in favor of
targeted biopsy. The positivity of systematic biopsy was 45%, whereas positivity for targeted biopsies
was 53.3%. The positivity of PI-RADS 3 lesions for targeted biopsies was 35%, 61% for PI-RADS
4, and 86% for PI-RADS 5. The median number of positive systematic cores was 3, and 4 cores for
targeted biopsies, while the median cancer core involvements were 30% for systematic and 60% for
targeted cores. In targeted cores, there was a higher percentage of ISUP grade 2 and 3 cancers when
compared with systematic cores. Targeted biopsy is a valuable addition to the standard systematic
biopsy in patients with suspicious lesions described on mpMRI.
Ključne riječi
Prostate cancer; Prostate biopsy; Targeted prostate biopsy; mpMRI
Hrčak ID:
322983
URI
Datum izdavanja:
30.4.2024.
Posjeta: 0 *